J. Stern & Co. LLP Acquires 7,515 Shares of Zoetis Inc. (NYSE:ZTS)

J. Stern & Co. LLP lifted its stake in Zoetis Inc. (NYSE:ZTS) by 4.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 189,147 shares of the company’s stock after buying an additional 7,515 shares during the period. Zoetis makes up approximately 3.9% of J. Stern & Co. LLP’s investment portfolio, making the stock its 13th biggest position. J. Stern & Co. LLP’s holdings in Zoetis were worth $32,791,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Aveo Capital Partners LLC bought a new position in shares of Zoetis in the fourth quarter worth $225,000. Gryphon Financial Partners LLC grew its stake in Zoetis by 11.8% during the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after buying an additional 322 shares in the last quarter. TrinityPoint Wealth LLC increased its holdings in Zoetis by 0.3% in the 4th quarter. TrinityPoint Wealth LLC now owns 22,319 shares of the company’s stock valued at $4,405,000 after buying an additional 73 shares during the period. Franklin Resources Inc. raised its position in shares of Zoetis by 8.9% in the 4th quarter. Franklin Resources Inc. now owns 161,489 shares of the company’s stock valued at $31,873,000 after buying an additional 13,236 shares in the last quarter. Finally, SageView Advisory Group LLC lifted its holdings in shares of Zoetis by 9.1% during the 4th quarter. SageView Advisory Group LLC now owns 5,553 shares of the company’s stock worth $1,063,000 after acquiring an additional 464 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 0.3 %

NYSE ZTS opened at $192.64 on Monday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The business’s fifty day moving average is $184.70 and its 200 day moving average is $174.33. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a market cap of $87.90 billion, a price-to-earnings ratio of 37.12, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same period last year, the firm posted $1.41 earnings per share. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, sell-side analysts expect that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler boosted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $220.38.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.